In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side ...

Healthy snacks are in demand as meals are being “swapped for grazing” as the rise of weight-loss jabs encourages a “change in ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that ...

Social media advertisements of weight-loss drugs such as Wegovy and Mounjaro is illegal as per the India law, lawyers tell ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective treatments. The gap between the scale of the problem and the funding response ...

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...

A review of recent trading activity reveals a short-term picture of weakness. In the latest session, Viking Therapeutics shares closed at $36.15, marking a decline of 2.51%. This performance ...

I am a 68-year-old female who was first diagnosed with osteopenia and now osteoporosis. My physician has highly recommended ...